NORD and the Galactosemia Foundation Jointly Publish First “Voice of the Patient” Report to Help Inform the FDA and Researchers
Galactosemia Foundation Urges FDA to Incorporate Voice of the Patient in Review of Potential First Treatment for Children with Life-Altering Rare Disease
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
The Hill Op Ed: The FDA is ignoring patients in clinical trials
Applied Pressure: After Regulatory Redirect, Mixed Trial Results Pose Challenges for Drugmaker and Patient Group
Support the Galactosemia Foundation during Rare Disease Month